T1	Participants 43 91	male patients with diffuse large B-cell lymphoma
T2	Participants 108 165	HD2002 prospective multicentre randomized phase III trial
T3	Participants 364 376	321 patients
T4	Participants 628 684	diffuse large B-cell lymphoma (DLBCL) subgroup (n = 152)
T5	Participants 790 825	male patients of the DLBCL subgroup
T6	Participants 1418 1442	male patients with DLBCL
